A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Latest Information Update: 15 Mar 2024
At a glance
- Drugs Pomalidomide (Primary) ; Bortezomib; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms OPTIMISMM
- Sponsors Celgene Corporation
- 01 Mar 2024 Results of Sub analysis assessing outcome by frailty and/or bortezomib dose adjustment published in the Clinical Lymphoma, Myeloma & Leukemia
- 07 Jul 2022 The trial has been completed in France and Denmark, according to European Clinical Trials Database record.
- 07 Jun 2022 Results ( Cut off : 26 Oct 2017) presented at the 58th Annual Meeting of the American Society of Clinical Oncology